Introduction {#s0001}
============

Advanced age is one of the most important risk factors for development of chronic obstructive pulmonary disease (COPD) and an increased number of senescent cells is a major feature of aging.[@cit0001] Recent advances COPD have implicated acceleration of cell senescence in both alveolar and airway epithelial cells, which is functionally characterized by impaired cell regeneration and aberrant cytokine secretion of the senescence-associated secretory phenotype (SASP), in COPD pathogenesis.[@cit0002]^,^[@cit0004] Although the molecular mechanism underlying cell senescence regulation is still unknown, reactive oxygen species (ROS) released during mitochondrial respiration has been generally implicated in the progression of cellular senescence.[@cit0003] Mitochondrial respiratory chain dysfunction accompanying enhanced ROS production can be attributed to cigarette smoke (CS) exposure, a main cause for COPD development.[@cit0011]

Mitochondrial quality is maintained via the optimal balance between biogenesis and degradation for renewal, and mitochondria are also highly dynamic organelles undergoing continuous fusion and fission cycles.[@cit0013] Fusion has been shown to rescue damaged mitochondria by redistributing proteins and by maintaining mitochondrial DNA integrity.[@cit0015] In case of more extensive damage, segregation of irreversibly damaged mitochondria through fission is a prerequisite for appropriate engulfment and degradation via mitochondria selective autophagy known as mitophagy.[@cit0016] Hence, orchestrated mitochondrial biogenesis, dynamics, and degradation by mitophagy constitute a series of quality control measures to prevent the accumulation of damaged mitochondria and excessive ROS production.[@cit0003]

Mitophagy is a highly conserved mechanism of selectively delivering unwanted mitochondria for lysosomal degradation.[@cit0016] Proteins localized on the mitochondrial outer membrane, including BNIP3L, BNIP3, and FUNDC1 (FUN14 domain containing 1), are specific receptors for mitophagic recognition during red blood cell maturation, metabolic stress, and hypoxia.[@cit0018] Thus far, the PINK1-PARK2 pathway has been largely implicated in the removal of damaged mitochondria with depolarized membranes.[@cit0022] Stress-induced membrane depolarization stabilizes PINK1, resulting in recruitment of PARK2, an E3-ubiquitin ligase, to mitochondria. PARK2-mediated ubiquitination of mitochondrial substrates, including BCL2, MFNs (mitofusins), and VDAC (voltage-dependent anion channel), is required for the binding of the receptor protein SQSTM1/p62, which can recognize both ubiquitinated substrates and microtubule-associated protein 1 light chain 3 (MAP1LC3/LC3) on phagophores, the precursor to autophagosomes.[@cit0017] Therefore, concomitant accumulation of SQSTM1 and ubiquitinated proteins is now widely recognized as at least partly reflecting insufficient autophagy, including mitophagy.[@cit0023]

In addition to accumulation of ubiquitinated proteins and SQSTM1 resulting from insufficient autophagic degradation, we have recently demonstrated an increase in fragmented mitochondria in the airway epithelial cells of COPD lung.[@cit0008] Furthermore, our in vitro experiments demonstrate that cigarette smoke extract (CSE)-induced accumulation of fragmented mitochondria is accompanied by increased mitochondrial ROS production and acceleration of human bronchial epithelial cell (HBEC) senescence.[@cit0024] Taken together, it is likely that insufficient mitophagic elimination is involved in the accumulation of fragmented mitochondria in response to CS exposure in COPD lung. Hence, we examined the involvement of the PINK1-PARK2 pathway for mitophagic elimination of damaged mitochondria in regulation of mitochondrial ROS production and cellular senescence in HBEC in the context of COPD pathogenesis.

Results {#s0002}
=======

CSE induces mitochondrial ROS production and cellular senescence in HBEC {#s0002-0001}
------------------------------------------------------------------------

We have recently reported that depolarized mitochondria-derived ROS is involved in the progression of cellular senescence in response to CSE exposure.[@cit0024] In line with this observation, MitoTracker Red staining demonstrated that CSE induced depolarization of the mitochondrial membrane potential ([**Fig. 1A**](#f0001){ref-type="fig"}). This was accompanied by increased ROS production as determined by the DCFH-DA assay for total ROS and DHR123 staining for mitochondrial ROS, respectively ([**Fig. 1B and C**](#f0001){ref-type="fig"}). To clarify the involvement of ROS in CSE-induced HBEC senescence, we performed western blotting of CDKN2A/p16 and CDKN1A/p21 (senescence-associated cyclin dependent kinase inhibitors). Increased CDKN2A and CDKN1A expression levels indicated acceleration of cellular senescence. Both N-acetylecysteine (NAC) (an efficient antioxidant for intracellular ROS) and Mito-TEMPO (a specific antioxidant for mitochondrial ROS) efficiently inhibited the increase of mitochondrial ROS production and cellular senescence mediated by CSE exposure ([**Fig. 1C and D**](#f0001){ref-type="fig"}). CSE-induced acceleration of HBEC senescence and efficient inhibition by antioxidant treatments were further confirmed by means of phospho-Histone H2AFX/H2A.X (Ser139) staining of DNA damage ([**Fig. 1E**](#f0001){ref-type="fig"}). Figure 1.CSE induces mitochondrial damage and ROS production accompanied by cell senescence in HBEC. (**A**) Fluorescence microscopy detection of Hoechst 33258 (left panels), MitoTracker Red staining (middle panels), and TOMM20 staining of mitochondria (right panels). HBEC were treated with CSE (1.0%) for 24 h (lower panels). Bar: 100 μm. (**B**) Fluorescence intensity of DCFH-DA staining for intracellular ROS production in response to CSE exposure. The fluorescence level in the control-treated cells was designated as a 1.0. \* *P* \< 0.05. (**C**) Fluorescence microscopy detection of Hoechst 33258 (upper panels) and DHR123 staining (lower panels). HBEC were pretreated with NAC (1 mM) and Mito-TEMPO (100 μM) for 3 h before CSE exposure, (1% CSE for 24 h). Bar: 20 μm. (**D**) Western blotting (WB) using anti-CDKN2A, anti-CDKN1A, and anti-ACTB in control-treated (lane 1, 2), NAC (1 mM)-treated (lane 3, 4), and Mito-TEMPO (100 μM)-treated (lane 5, 6) HBEC. Pretreatment with NAC (1 mM) and Mito-TEMPO (100 μM) for 3 h before CSE exposure, (1% for 48 h). Middle panel is the average (±SEM) of the relative increase in CDKN2A normalized to ACTB and the right panel is the average (±SEM) of the relative increase in CDKN1A normalized to ACTB, which are taken from densitometric analysis of WB from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05. (**E**) Photographs of immunofluorescent staining of phospho-Histone H2AFX (Ser139) in HBEC treated with CSE (1.0%) for 48 h in the absence or presence of NAC (1 mM) and Mito-TEMPO (100 μM). Bar: 100 μm. Shown in the right panel is the percentage (±SEM) of phospho-histone H2AFX (Ser139)-positive cells from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05.

Involvement of mitophagy in regulation of CSE-induced ROS production {#s0002-0002}
--------------------------------------------------------------------

To examine the autophagic degradation of mitochondria (mitophagy) in response to CSE exposure, confocal microscopy was performed in BEAS-2B cells stably expressing EGFP-LC3B. Colocalization of TOMM20-stained mitochondria and EGFP-LC3B dots was used to determine autophagosome formation. Although CSE induced EGFP-LC3B dot formation, colocalization with mitochondria was barely detected in the absence of bafilomycin A1 (Baf A1), an inhibitor of autolysosomal maturation ([**Fig. 2A**](#f0002){ref-type="fig"}). Baf A1 treatment alone induced EGFP-LC3B dot formation accompanied by limited colocalization with TOMM20-stained mitochondria (yellow dots), indicating baseline mitophagy ([**Fig. 2A**](#f0002){ref-type="fig"}). CSE treatment markedly enhanced EGFP-LC3B dot formation with concomitant colocalization with TOMM20-stained mitochondria in the presence of Baf A1 ([**Fig. 2A**](#f0002){ref-type="fig"}), indicating CSE-induced mitophagy activation. Consistent with our recent finding, accumulation of fragmented mitochondria was also observed following CSE treatment, especially in the presence of Baf A1.[@cit0024] CSE-induced mitophagy was further confirmed in HBEC by electron microscopy (EM) evaluation. CSE treatment slightly but significantly increased the number of autophagic vacuoles containing mainly deforming mitochondria, which was markedly enhanced by concomitant Baf A1 treatment ([**Fig. 2B**](#f0002){ref-type="fig"}**; Fig. S1**). CSE treatment decreased total mitochondria count with an increased ratio of fragmented mitochondria. Concomitant Baf A1 treatment significantly enhanced cytoplasmic accumulation of fragmented mitochondria ([**Fig. 2B**](#f0002){ref-type="fig"}**; Fig. S1**). In contrast to Baf A1, Torin1, an autophagy inducer, demonstrated only a slight increase in the number of autophagosomes and mitochondria, but enhanced degradation of mitochondria inside of autophagic vacuoles, which appeared to be associated with significant decrease in the number of fragmented mitochondria in the cytoplasm ([**Fig. 2B**](#f0002){ref-type="fig"}**; Fig. S1**). Figure 2.CSE induces mitophagy and mitochondrial ROS production in HBEC. (**A**) Colocalization analysis of confocal laser scanning microscopy images of TOMM20 staining and EGFP-LC3B. *pEGFP-LC3B* expressing BEAS-2B cells were treated with CSE (1.0%) for 48 h in the presence or absence of bafilomycin A~1~ (Baf A1, 200 nM). Bar: 20 μm (**B**) Electron microscopy detection of mitochondria and autophagosomes in HBEC. HBEC were treated with CSE (1.0%) for 48 h in the absence or presence of Baf A1 (200 nM) and Torin1 (250 nM). Bar: 2 μm. The middle panel is the average (±SEM) count of autophagosomes taken from a 10-image field (10000 X) for each sample. Open bar is total autophagosomes, filled bar is autophagosomes containing mitochondria. \**P* \< 0.05. The lower panel is the average (±SEM) count of mitochondria taken from 10 image fields (10000 X) for each sample. Mitochondria shorter than 1 μm without fusion to other mitochondria were counted as fragmented. Open bar is total mitochondria, filled bar is fragmented mitochondria. \**P* \< 0.05, \*\**P* \< 0.001. (**C**) WB using anti-ubiquitin, anti-SQSTM1, and anti-TOMM20 in the presence of Baf A1 (200 nM) (lane 3, 4) and Torin1 (250 nM) (lane 5, 6). HBEC were treated with CSE (1.0%) for 48 h and protein samples from mitochondrial fractions were collected. Shown is a representative experiment of 4 showing similar results. The middle panel is the average (±SEM) relative increase in ubiquitin normalized to TOMM20 and the lower panel is the average (±SEM) relative increase in SQSTM1 normalized to TOMM20, taken from densitometric analysis of WB from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05, \*\**P* \< 0.001. (**D**) Fluorescence intensity of DCFH-DA staining for intracellular ROS production in response to CSE exposure. HBEC were treated with CSE (1.0%, 1 h) in the presence of Baf A1 (200 nM) (lane 3, 4) and Torin1 (250 nM) (lane 5, 6). The fluorescence level in the control-treated cells was designated as 1.0 and shown in panel is the average (±SEM). Open bar is no treatment, filled bar is CSE-treated.\* *P* \< 0.05. (**E**) MitoSOX Red staining for mitochondrial ROS production. Fluorescence microscopy detection was performed. HBECs were treated with CSE (1.0%) for 24 h in the presence of Baf A1 (200 nM) (middle panels) and Torin1 (250 nM) (right panels). Bar: 20 μm.

PARK2-induced ubiquitination of mitochondrial substrates is a prerequisite for the binding of the autophagy receptor protein SQSTM1,[@cit0017] hence accumulation of ubiquitinated proteins and SQSTM1 in the mitochondrial fraction can be interpreted as reflecting increased mitochondrial damage without sufficient elimination. Significantly increased expression levels of both ubiquitinated proteins and SQSTM1 were observed in the mitochondrial fraction following CSE treatment, which was further enhanced in the presence of Baf A1. Conversely, Torin1 reduced accumulations of ubiquitinated protein and SQSTM1. These data suggest incomplete mitophagic degradation of damaged mitochondria in the setting of CSE exposure in HBEC ([**Fig. 2C**](#f0002){ref-type="fig"}). Next, to evaluate the association between mitophagy and ROS production, we performed DCFH-DA assays and MitoSOX Red staining in HBEC ([**Fig. 2D and E**](#f0002){ref-type="fig"}). Consistent with accumulations of damaged mitochondria, Baf A1 significantly enhanced CSE-induced total and mitochondrial ROS production, which was reduced by Torin1. These data suggest a causal link between insufficient mitophagy and excessive ROS production. Taken together, mitophagy may play a key regulatory role in the elimination of CSE-induced mitochondrial damage and ROS production in HBEC.

PINK1 regulates mitophagy, cellular senescence, and PARK2 recruitment to mitochondria in response to CSE exposure in HBEC {#s0002-0003}
-------------------------------------------------------------------------------------------------------------------------

To clarify the involvement of PINK1 in mitophagy and PARK2 recruitment to the mitochondrial fraction, *PINK1* siRNA was employed and efficient knockdown was observed by western blotting ([**Fig. 3E**](#f0003){ref-type="fig"}). Confocal microscopy evaluation was performed in control and *PINK1* siRNA-transfected BEAS-2B cells. *PINK1* siRNA-transfected BEAS-2B cells exhibited a marked decrease in colocalization of TOMM20-stained mitochondria and EGFP-LC3B dots (autophagosome) in response to CSE exposure ([**Fig. 3A**](#f0003){ref-type="fig"}). *PINK1* knockdown also enhanced CSE-induced mitochondrial ROS production and HBEC senescence ([**Fig. 3B to E**](#f0003){ref-type="fig"}). *PINK1* knockdown noticeably reduced PARK2-HA levels in the mitochondrial fraction, while increased PARK2-HA levels were observed in the cytosolic fraction in *PARK2-HA*-transfected HBEC, supporting the notion that PINK1 is responsible for translocation of PARK2 from the cytoplasm to the mitochondria ([**Fig. 3F**](#f0003){ref-type="fig"}). The involvement of PINK1 in PARK2 recruitment to the mitochondria was once again demonstrated via a decrease in colocalization of TOMM20 staining of mitochondria and PARK2-HA in response to CSE exposure in *PINK1* knockdown HBEC ([**Fig. 3G**](#f0003){ref-type="fig"}). Figure 3 (See previous page).PINK1 regulates CSE-induced mitophagy, ROS production, cell senescence, and PARK2 recruitment to mitochondria in HBEC. (**A**) Colocalization analysis of confocal laser scanning microscopy images of TOMM20 staining and EGFP-LC3B. *pEGFP-LC3B* expressing BEAS-2B cells were transfected with nonsilencing control siRNA and *PINK1* siRNA, and CSE treatment (1.0%) was started 24 h post-siRNA transfection. After 24 h treatment with CSE, BEAS-2B cells were fixed for staining. Bar: 20 μm (**B**) Photographs of fluorescence staining of control or CSE (1.0%) treated HBEC with Hoechst 33258 (left panels) and with MitoSOX Red (right panels). HBEC were transfected with nonsilencing control siRNA and *PINK1* siRNA, and CSE treatment (1.0%) was started 24 h post-siRNA transfection. HBEC were treated with CSE for *24 h*. Bar: 100 μm (**C**) Fluorescence intensity of DCFH-DA staining for intracellular ROS production in response to CSE exposure. HBEC were transfected with nonsilencing control siRNA and *PINK1* siRNA, and CSE treatment (1.0%) was started 24 h post-siRNA transfection. The fluorescence level in the control-treated cells was designated as 1.0 and shown in panel is the average (±SEM). Open bar is no treatment, filled bar is CSE-treated.\**P* \< 0.05. (**D**) SA-β-gal staining of control or *PINK1* siRNA-transfected HBEC. CSE treatment (1.0%) was started 24 h post-siRNA transfection and staining was performed after 48 h treatment. Shown is the percentage (±SEM) of SA-β-gal-positive cells from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05. (**E**) WB using anti-CDKN1A and anti-ACTB in nonsilencing control siRNA-transfected (lane 1, 2) and *PINK1* siRNA-transfected HBEC (lane 3, 4). CSE treatment (1.0%) was started 24 h post-siRNA transfection and protein samples were collected after 48 h treatment. Shown is a representative experiment of 3 with similar results. The lower panel is the average (±SEM) relative increase in CDKN1A normalized to ACTB, taken from densitometric analysis of WB from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05, \*\**P* \< 0.001. (**F**) WB using anti-PARK2, anti-TOMM20, and anti-ACTB in *PARK2-HA* vector and nonsilencing control siRNA-transfected (lane1, 2), and *PARK2-HA* vector and *PINK1* siRNA-transfected HBEC (lane 3, 4). CSE treatment (1.0%) was started 24 h post-transfection and protein samples for mitochondrial and cytosolic fractions were collected after 48 h treatment. Shown is a representative experiment of 3 showing similar results. The middle panel is the average (±SEM) relative increase in PARK2-HA normalized to TOMM20 in mitochondrial fraction, taken from densitometric analysis of WB from 4 independent experiments. Open bar is no treatment, filled bar is CSE-treated. The right panel is the average (±SEM) relative increase in PARK2-HA normalized to ACTB in cytosolic fraction, taken from densitometric analysis of WB from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05. (**G**) Photographs of fluorescence staining in HBEC transfected with *PARK2-HA* vector and control siRNA or *PARK2-HA* vector and *PINK1* siRNA. CSE treatment (1.0%) was started 24 h post-transfection and staining was performed after 24 h treatment. PARK2 expression was detected using an anti-HA antibody and anti-TOMM20 antibody was used for mitochondria. Pseudocolored and merged images of PARK2-HA and TOMM20 were created (Adobe photoshop) from images acquired using a digital imaging system. Bar: 10 μm.

PARK2 regulates mitophagy, ROS production, and cellular senescence in response to CSE exposure in HBEC {#s0002-0004}
------------------------------------------------------------------------------------------------------

PARK2 expression levels were slightly increased in the mitochondrial fraction in response to CSE exposure ([**Fig. 4A**](#f0004){ref-type="fig"}) and PARK2 has been proposed to regulate ubiquitination of mitochondrial substrates.[@cit0022] To clarify the involvement of PARK2 in regulation of ubiquitination with concomitant SQSTM1 accumulation in the mitochondrial fraction, we employed siRNA for *PARK2*, which resulted in an efficient knockdown that was observed by western blotting ([**Fig. 4A**](#f0004){ref-type="fig"}). CSE-induced accumulation of ubiquitinated proteins and SQSTM1 in the mitochondrial fraction was appreciably reduced by *PARK2* knockdown ([**Fig. 4A**](#f0004){ref-type="fig"}). To confirm the regulatory role of PARK2 in mitophagy, confocal microscopy evaluation was performed in control and *PARK2* siRNA-transfected BEAS-2B cells ([**Fig. 4B**](#f0004){ref-type="fig"}). Consistent with *PINK1* knockdown experiments, *PARK2* siRNA-transfected BEAS-2B cells exhibited a marked decrease in colocalization of TOMM20-stained mitochondria and EGFP-LC3B dots after CSE treatment. Intriguingly, CSE-induced EGFP-LC3B dot formation was also decreased by *PARK2* knockdown, suggesting the potential involvement of PARK2 in not only ubiquitination for mitophagic recognition but also in autophagosome formation following CSE exposure. Involvement of PARK2 in mitophagy was further confirmed by demonstrating the colocalization of EGFP-LC3B dots and PARK2 in response to CSE exposure in *PARK2-HA*-transfected BEAS-2B cells ([**Fig. 4C**](#f0004){ref-type="fig"}). *PARK2* knockdown also enhanced CSE-induced mitochondrial ROS production shown by DCFH-DA assay and MitoSOX Red staining ([**Fig. 4D and E**](#f0004){ref-type="fig"}) and also enhanced HBEC senescence in response to CSE exposure as measured by SA-β-gal staining and expression of CDKN1A ([**Fig. 4F and G**](#f0004){ref-type="fig"}). The regulatory role of PARK2 in mitophagy was further confirmed by transfection experiments of *PARK2-HA*. PARK2 overexpression efficiently reduced mitochondrial ROS production and HBEC senescence by CSE exposure ([**Fig. 4H and I**](#f0004){ref-type="fig"}). Figure 4 (See previous page).PARK2 regulates CSE-induced mitochondrial ROS production and cellular senescence in HBEC. (**A**) WB using anti-ubiquitin, anti-SQSTM1, anti-PARK2, and anti-TOMM20 in nonsilencing control siRNA (lane 1, 2) and *PARK2* siRNA-transfected HBEC (lane 3, 4). CSE treatment (1.0%) was started 24 h post-siRNA transfection and protein samples from mitochondrial fractions were collected after 48 h treatment. Shown is a representative experiment of 3 showing similar results. The middle panel is the average (±SEM) relative increase in ubiquitin normalized to TOMM20 and the right panel is the average (±SEM) relative increase in SQSTM1 normalized to TOMM20, which are taken from densitometric analysis of WB from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05. (**B**) Colocalization analysis of confocal laser scanning microscopy images of TOMM20 staining and EGFP-LC3B. *pEGFP-LC3B* -expressing BEAS-2B cells were transfected with a nonsilencing control siRNA and *PARK2* siRNA, and CSE treatment (1.0%) was started 24 h post-siRNA transfection. After 24 h treatment with CSE, BEAS-2B cells were fixed for staining. Bar: 20 μm (**C**) Photographs of fluorescence staining of control or CSE (1.0%)-treated BEAS-2B cells expressing EGFP-LC3B in the presence of Baf A1. BEAS-2B cells were transfected with *PARK2-HA* expression vector and PARK2 expression was detected using an anti-HA antibody. Pseudocolored and merged images of PARK2-HA and EGFP-LC3B were created (Adobe photoshop) from images acquired using a digital imaging system. Bar: 10 μm (**D**) Fluorescence intensity of DCFH-DA staining for intracellular ROS production in response to CSE exposure. HBEC were transfected with nonsilencing control siRNA and *PARK2* siRNA, and CSE treatment (1.0%) was started 24 h post-siRNA transfection. The fluorescence level in the control treated cells was designated as 1.0 and shown in panel is the average (±SEM). Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05, \*\**P* \< 0.001. (**E**) Photographs of Hoechst 33258 (upper panels) and MitoSOX Red (lower panels) fluorescence staining in control or CSE (1.0%)-treated HBEC. HBEC were transfected with nonsilencing control siRNA and *PARK2* siRNA, and CSE treatment (1.0%) was started 24 h post-siRNA transfection. HBEC were treated with CSE for 24 h. Bar: 50 μm (**F**) SA-β-gal staining of control or *PARK2* siRNA-transfected HBEC. CSE treatment (1.0%) was started 24 h post-siRNA transfection and staining was performed after 48 h treatment. Shown is the percentage (±SEM) of SA-β-gal-positive cells from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05, \*\**P* \< 0.001. (**G**) WB using anti-CDKN1A and anti-ACTB in nonsilencing control siRNA-transfected (lane 1, 2) and *PARK2* siRNA-transfected HBEC (lane 3, 4). CSE treatment (1.0%) was started 24 h post-siRNA transfection and protein samples were collected after 48 h treatment. Shown is a representative experiment of 3 showing similar results. The right panel is the average (±SEM) of relative increase in CDKN1A normalized to ACTB, taken from densitometric analysis of WB from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05, \*\**P* \< 0.001. (**H**) Photographs of Hoechst 33258 (upper panels) and MitoSOX Red (lower panels) fluorescence staining in control or CSE (1.0%)-treated HBEC. HBEC were transfected with control and *PARK2-HA* expression vector, and CSE treatment (1.0%) was started 24 h post transfection. HBEC were treated with CSE for 24 h. (**I**) WB using anti-PARK2, anti-CDKN1A, and anti-ACTB in control vector-transfected (lane 1, 2) and *PARK2-HA* expression vector-transfected HBEC (lane 3, 4). CSE treatment (1.0%) was started 24 h post-transfection and protein samples were collected after 48 h treatment. Shown is a representative experiment of 3 showing similar results. The lower panel is the average (±SEM) of relative increase in CDKN1A normalized to ACTB, taken from densitometric analysis of WB from 3 independent experiments. Open bar is no treatment, filled bar is CSE-treated. \**P* \< 0.05, \*\**P* \< 0.001.

Decreased PARK2 expression levels in lung from COPD patients {#s0002-0005}
------------------------------------------------------------

To clarify the importance of PINK1-PARK2 pathway-mediated mitophagy in COPD pathogenesis, we examined the protein expression levels of PINK1 and PARK2 in lung homogenates from nonsmokers (n = 10), non-COPD smokers (n = 10), and COPD patients (n = 10), respectively. The smoking index (pack year) was significantly different from nonsmokers but there was no difference between non-COPD smokers and COPD ([**Table 1**](#t0001){ref-type="table"}). In line with recent findings of increased expression in bronchial epithelial cells from COPD patients, PINK1 tended to be highly expressed in lung homogenates from COPD patients, which may reflect accumulation of damaged mitochondria ([**Fig. 5A**](#f0005){ref-type="fig"}).[@cit0026] However, PINK1 demonstrated no significant correlation with percentage of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ([**Fig. 5B**](#f0005){ref-type="fig"}). Conversely, significantly lower expression levels of PARK2 were detected in lung homogenates from COPD patients compared to those in lung homogenates from non-COPD smokers. Interestingly, a slight increase in PARK2 expression levels was observed in lung homogenates from non-COPD smokers. Furthermore, PARK2 expression levels were positively correlated with percentage of FEV1/FVC ([**Fig. 5C and D**](#f0005){ref-type="fig"}). Table 1.Patient characteristics (for lung homogenates)Nonsmoker (n = 10)Non-COPD smoker (n = 10)COPD (n = 10)p valueAge, years65.0 ± 14.669.0 ± 7.969.3 ± 8.1NSMale, % of group20.090.090.0NASI (pack year)056.9 ± 28.9\*48.2 ± 25.4\*\<0.001FEV1/FVC (%)75.3 ± 8.577.1±3.961.1 ± 7.8\*\<0.001[^1] Figure 5.PINK1 and PARK2 expression levels in lung homogenates. (**A**) WB using anti-PINK1 and anti-ACTB of lung homogenates from nonsmoker, smoker without COPD, and COPD. The lower panel is the average (±SEM) taken from densitometric analysis of WB. Open bar is nonsmoker (n = 10), filled bar is smoker without COPD (n = 10), and horizontal crosshatched bar is COPD (n = 10). (**B**) Shown is the relationship between relative PINK1 expression normalized to ACTB and the percentages of FEV1/FVC (n = 30). (**C**) WB using anti-PARK2 and anti-ACTB of lung homogenates from nonsmoker, smoker without COPD, and COPD. The lower panel is the average (±SEM) taken from densitometric analysis of WB. Open bar is nonsmoker (n = 10), filled bar is smoker without COPD (n = 10), and horizontal crosshatched bar is COPD (n = 10). \**P* \< 0.05. (**D**) Shown is the relationship between relative PARK2 expression normalized to ACTB and the percentages of FEV1/FVC (n = 30).

To further elucidate the physiological relevance of PARK2 expression levels in COPD pathogenesis, we performed immunohistochemical evaluations of PARK2 in nonsmokers ([**Fig. 6A and B**](#f0006){ref-type="fig"}), non-COPD smokers ([**Fig. 6C and D**](#f0006){ref-type="fig"}), and COPD lungs ([**Fig. 6E to H**](#f0006){ref-type="fig"}). Patient characteristics are presented in [**Table 2**](#t0002){ref-type="table"}. Airway epithelial cells are known to be representative cells in the expression of high levels of PARK2 in lung tissue. In line with results in lung homogenate, airway epithelial cells in small airways exhibited significantly decreased expression levels of PARK2 in COPD lungs compared to those in lungs from nonsmokers and non-COPD smokers ([**Fig. 6I**](#f0006){ref-type="fig"}). Table 2.Patient characteristics (for immunohistochemistry)CaseAgeSexSmoking indexFEV1/FVC (%)%FEV1(%)A34F095.790.8B48F070.797.2C65M5077.7117.8D77M8074.8121.4E64M6468.288.9F61M4068.684.1G64M4457.099.6H60M8868.181.0[^2] Figure 6.PARK2 expression in normal and COPD lung tissues. Immunohistochemical staining of PARK2 in nonsmoker, non-COPD smoker, and COPD lung tissues: Photomicrographs of small airway in nonsmoker (**A** and **B**), non-COPD smoker (**C** and **D**), and COPD lungs (**E to H**). Bar: 100 μm in **A**, **B**, **G**, **H**. Bar = 50 μm in **C**, **D**, **E**, **F**. (**I**) Shown is the average of semiquantitative score (±SEM) of PARK2-positive cells in small airway epithelial cells. Open bar is non-COPD (n = 4, total 18 small airways) and filled bar is COPD (n = 4, total 16 small airways). \**P* \< 0.05.

Taken together, reduced PARK2 expression levels in small airway epithelial cells might be associated with insufficient mitophagy and accelerated cell senescence as a part of the pathogenic sequence of COPD development ([**Fig. 7**](#f0007){ref-type="fig"}). Figure 7.Hypothetical model of involvement of mitophagy in the regulation of cell fate by smoking stress in COPD pathogenesis. Insufficient mitophagy, which can be attributed to reduced PARK2 expression, results in accumulation of damaged mitochondria in response to cigarette smoke exposure. Accumulation of damaged mitochondria accompanied by increased reactive oxygen species production induces cellular senescence. Conversely, excessive mitophagy activation accompanied by serious mitochondrial damage in response to severe smoking stress may induce PCD, including apoptosis and necroptosis. Mitophagy may lead to either senescence or PCD depending on the amount of damage as a part of COPD pathogenesis.

Discussion {#s0003}
==========

Damaged mitochondria are major sources of aberrant ROS production and mitochondrial quality control has been proposed to be a critical determinant in cell fate, including senescence.[@cit0010] In this study, we demonstrate that mitophagic elimination of damaged mitochondria has a pivotal role in regulation of mitochondrial ROS production, which is involved in acceleration of HBEC senescence in response to CSE exposure. *PINK1* and *PARK2* knockdown experiments clarify that both PINK1 and PARK2 are essential for mitophagy in response to CSE exposure and PINK1-mediated recruitment of PARK2 to mitochondria appears to be a prerequisite for ubiquitination and mitophagic recognition ([**Fig. 3 and 4**](#f0003 f0004){ref-type="fig"}). Furthermore, we see positive correlation between PARK2 expression levels in lung homogenates and lung function, and immunohistochemistry shows a decrease in PARK2 expression in airway epithelial cells of COPD lungs, suggesting a clinical implication for reduced PARK2 expression in COPD pathogenesis. Conversely modestly increased PINK1 levels may reflect accumulation of damaged mitochondria, which is conferred by insufficient mitophagic degradation in COPD lung.

Improper mitophagic elimination of damaged mitochondria has been implicated in the pathogenesis of a variety of diseases,[@cit0010] and we have recently demonstrated insufficient autophagy in COPD lung.[@cit0008] Hence, we assumed that our findings of accumulations of fragmented mitochondria might result from insufficient mitophagy in the airway epithelial cells of COPD lung and also in CSE-exposed HBEC.[@cit0008] Supporting this notion, autophagy and mitophagy activation induced by Torin1 resulted in enhanced degradation of autophagosomal contents including mitochondrial debris and an increase in undamaged mitochondrial number as shown by EM, and also reduced CSE-induced accumulation of ubiquitinated proteins and SQSTM1 in the mitochondrial fraction of HBEC ([**Fig. 2**](#f0002){ref-type="fig"}). Furthermore, Torin1 attenuated mitochondrial ROS production in response to CSE exposure ([**Fig. 2**](#f0002){ref-type="fig"}), suggesting the involvement of mitophagic regulation of damaged mitochondria accompanied by enhanced ROS production in cigarette-induced lung pathology.

In line with the recent findings of aging-associated neurodegenerative disorders,[@cit0028] the PINK1-PARK2 pathway is involved in regulating the mitophagic elimination of CSE-induced damaged mitochondria that modulates ROS production and cellular senescence in HBEC ([**Fig. 3 and 4**](#f0003 f0004){ref-type="fig"}). Although PINK1 and PARK2 are both crucial for mitophagy,[@cit0030] a recent paper shows upregulation of PINK1 in COPD lung, which is interpreted as reflecting accumulation of mitochondrial damage.[@cit0026] Consistently, we observed modestly increased PINK1 levels in lung homogenates from COPD patients, whereas PARK2 levels were decreased and there was a positive correlation between PARK2 levels and percentage of FEV1/FVC ([**Fig. 5 and 6**](#f0005 f0006){ref-type="fig"}). Additionally, PARK2 levels in non-COPD smokers tend to be higher than those in control lung, indicating the possibility that PARK2 expression in airway epithelial cells is a critical determination of not only mitophagy activity but also predisposition to cigarette-induced COPD development. It has been reported that PARK2 overexpression increases mitochondrial activity during aging in association with life-span extension, further supporting the notion that PARK2 has a pivotal role in mitochondrial quality control in terms of regulation of senescence-associated disorders.[@cit0031] However, the precise mechanism for the decrease in PARK2 levels in COPD lung remains unclear. Furthermore, several lines of evidence demonstrate the participation of other receptors during autophagosomal recognition of mitochondria, including BNIP3L, BNIP3, and FUNDC1, hence the potential involvement of those receptors in mitophagy regulation of cigarette-induced cellular senescence need to be examined in future studies.[@cit0018]

Programmed cell death (PCD) has been widely implicated in COPD pathogenesis and the involvement of autophagy, including mitophagy, has been reported in not only apoptosis but also programmed necrosis, necroptosis.[@cit0032] The central purpose of both PCD and cell senescence is eliminating damaged cells for tissue regeneration, indicating that the extent of cell damage may be critical for determination of cell fate.[@cit0034] In contrast to our finding of a protective role for mitophagy in cell senescence induced by lower concentration of CSE (1.0%), a recent paper showing involvement of PINK1-mediated mitophagy in necroptosis used higher concentration of CSE (20%),[@cit0032] raising the following possibilities. First, excessive mitophagy activation by lethal stress may induce PCD, suggesting that mitophagy can lead to either PCD or senescence depending on the amount of damage. In other words, once a certain threshold of mitochondrial damage is reached, the choice is made by mitophagy between PCD and senescence ([**Fig. 7**](#f0007){ref-type="fig"}). Second, PINK1 has been shown to induce not only mitophagy but also mitochondrial depolarization during CSE exposure, indicating that PINK1-mediated mitochondrial damage has a dominant role in the setting of higher concentrations of CSE, resulting in PCD.[@cit0032] Mitochondrial division inhibitor-1 (Mdivi-1), which was used as a mitophagy inhibitor for necroptosis reduction,[@cit0032] has also been known to attenuate mitochondrial damage via inhibition of mitochondrial fission and mitochondrial outer membrane permeabilization (MOMP), suggesting that both mitophagy and mitochondrial integrity have a key regulatory role in determining cell fate in response to CSE exposure.

Although we have demonstrated the involvement of insufficient mitophagy-mediated ROS production in regulation of CSE-induced HBEC senescence, a causal link between mitochondrial ROS and cellular senescence remains controversial.[@cit0003] Intriguingly, recent advances demonstrate that mitophagy also controls inflammatory reactions. Inappropriate mitophagic degradation of mitochondrial DNA induces inflammatory reactions through TLR9 (toll-like receptor 9) recognition and activation of the NALP3 inflammasome.[@cit0035] Although a direct contribution of TLR9 and inflammasome activation to COPD pathogenesis is still unclear,[@cit0037] IL1B/interleukin 1β, a representative senescence-associated secretory phenotype (SASP) factor involved in COPD development,[@cit0039] is produced and activated through TLR9 signaling and inflammasome machinery.[@cit0041] Accordingly, insufficient mitophagy-mediated cell autonomous activation of TLR9 and the inflammasome may partly explain persistent inflammation after smoking cessation, which may also be associated with inflammation-mediated acceleration of cell senescence during COPD progression.[@cit0043] However, we understand the potential limitations of our in vitro experimental models using short-term CSE exposure to elucidate the mechanisms for COPD development. To clarify the clinical relevance of mitophagy in COPD pathogenesis, future studies need to be performed using appropriate animal models for COPD development in conjunction with mitophagy alteration, specifically modulation of the PINK1-PARK2 pathway.

In summary, we demonstrated that the PINK1-PARK2 pathway is involved in the modulation of CSE-induced HBEC senescence through the regulation of mitophagy and mitochondrial ROS production. Reduced PARK2 expression levels in COPD lung further support the notion that insufficient mitophagy is a part of the pathogenic sequence of COPD development, which may at least partly explain the mechanism for our recent findings of insufficient autophagy in COPD lung.[@cit0008] Therefore, modalities to achieve specific and appropriate levels of mitophagy activation may be a promising therapeutic option to regulate the aging-associated pathology, COPD.

Materials and Methods {#s0004}
=====================

Cell culture, antibodies, and reagents {#s0004-0001}
--------------------------------------

Normal airways were obtained from 1st through 4st order bronchi from pneumonectomy and lobectomy specimens for primary lung cancer. Informed consent was obtained from all surgical participants as part of an approved ongoing research protocol by the ethics committee of Jikei University School of Medicine. HBEC were isolated with protease treatment and characterized as previously described.[@cit0040] HBEC were serially passaged and used for experiments until passage 3. The majority of experiments were performed with HBEC from non-COPD patients. The bronchial epithelial cell line BEAS-2B was cultured in RPMI1640 (Gibco Life Technologies, 11875-093) with 10% fetal calf serum (Gibco Life Technologies, 26140-079) and penicillin-streptomycin (Gibco Life Technologies, 15140-122).

Antibodies used were rabbit anti-CDKN1A (Cell Signaling Technology, 2947), rabbit anti-CDKN2A (Santa Cruz Biotechnology, sc-468), rabbit anti-phospho-histone H2AFX/H2A.X (Ser139) (Cell Signaling Technology, 2577), mouse anti-poly- and monoubiquitin (Enzo Life Sciences, BML-PW8810), rabbit anti-SQSTM1 (MBL, PM045), rabbit anti-PARK2 (Cell Signaling Technology, 2132), rabbit anti-PINK1 (Abcam, ab23707), rabbit anti-hemagglutinin (HA) (Cell Signaling Technology, 3724), and mouse anti-ACTB (Sigma-Aldrich, A5316). Bafilomycin A~1~ (Baf A1) (Sigma-Aldrich, B1793), Torin 1 (Tocris Bioscience, 4247), Hoechst 33258 (Sigma-Aldrich, 861405), Dihydrorhodamine (DHR) 123 (Molecular Probes-Life Technologies, D23806), MitoSOX Red (Molecular Probes-Life technologies, M36008), N-acetylcysteine (NAC; Wako, 017-01531), Mito-TEMPO (Enzo Life Sciences, ALX-430-150), and rat tail COL1/type-I collagen (Sigma-Aldrich, C3867) were purchased.

Plasmids, siRNA, and transfection {#s0004-0002}
---------------------------------

The *LC3B* cDNA was the kind gift of Dr. Mizushima (Tokyo University, Tokyo, Japan) and Dr. Yoshimori (Osaka University, Osaka, Japan), and was cloned into *pEGFP-C1* vector.[@cit0044] *PARK2* expression vector was obtained from Addgene (Addgene, 17613). Small interfering RNA (siRNA) targeting *PARK2* (Applied Biosystems Life Technologies, s10043, s10044), *PINK1* (Applied Biosystems Life Technologies, s35166, s35167), and negative control siRNAs (Applied Biosystems Life Technologies, AM4635, AM4641) were purchased from Life Technologies. Specific knockdowns of *PARK2* and *PINK1* were validated using 2 different siRNAs, respectively. The *pEGFP-LC3B* plasmid was transfected into BEAS-2B cells using Lipofectamine 2000 (Invitrogen Life Technologies, 11668-027) and stably expressing clones were selected by culturing with G418 (Wako, 070-05183; 1.0 mg/ml) containing medium. Transfections of HBEC were performed using the Neon® Transfection System (Invitrogen Life Technologies, MPK5000), using matched optimized transfection kits (Invitrogen Life Technologies, MPK10096).

Preparation of cigarette smoke extract (CSE) {#s0004-0003}
--------------------------------------------

Cigarette smoke extract (CSE) was prepared as previously described with minor modifications.[@cit0008] Forty milliliters of cigarette smoke were drawn into the syringe and slowly bubbled into sterile serum-free cell culture media in 15-ml BD falcon tubes. One cigarette was used for the preparation of 10 mL of solution. CSE solution was filtered (0.22 μm; Merck Millipore, SLGS033SS) to remove insoluble particles and was designated as a 100% CSE solution.

Mitochondria isolation {#s0004-0004}
----------------------

Mitochondria and cytosolic fractions were isolated from HBECs with a commercially available kit (Thermo Fisher Scientific, 89874) according to the manufacturer\'s instructions.

Electron microscopy (EM) and immunocytochemistry {#s0004-0005}
------------------------------------------------

HBEC were treated with CSE (1.0%) in the presence or absence of Baf A1 and Torin1 for 48 h. After treatment, HBEC were fixed with 2% glutaraldehyde/0.1 M phosphate buffer (pH7.4) and in 1% osmium tetroxide/0.1 M phosphate buffer (pH7.4), and dehydrated with a graded series of ethanol. Fixed HBEC were then embedded in epoxy resin. Ultrathin sections were stained with uranyl acetate and lead citrate and observed with the Hitachi H-7500 transmission electron microscope (Hitachi, Tokyo, Japan). For quantitative evaluation of autophagosomes and mitochondria in HBEC, 10 image fields (10000 X) were selected for each sample. Mitochondria shorter than 1 μm without fusion to other mitochondria were counted as fragmented.

Immunohistochemistry and Immunofluorescence staining {#s0004-0006}
----------------------------------------------------

Immunohistochemical staining was performed as previously described with minor modification on the paraffin-embedded lung tissues.[@cit0007] PARK2 immunostaining were assessed by counting total and positively staining cells in small airways at a magnification of ×400 and percentage of positive staining was scored in a semi-quantitative fashion; 0 (less than 10%), 1 (11 to 49%), and 2 (more than 50%). Immunofluorescence staining was also performed as previously described.[@cit0007] BEAS-2B cells expressing EGFP-LC3B grown on 8-well culture slides were fixed with 4% paraformaldehyde for 15 min followed by permeabilization with 0.03% Triton X-100 (Wako, 160-24751) for 60 min. After blocking with 0.1% BSA (Sigma-Aldrich, A2153) for 60 min, the primary and secondary antibodies were applied according to the manufacturer\'s instructions. Confocal laser scanning microscopy analysis of mitochondria was performed by TOMM20 staining, assessed with a confocal microscope (Carl Zeiss LSM510, Tokyo, Japan). Fluorescence microscopy analysis of phospho-histone H2AFX, and TOMM20 staining were performed in HBEC (Olympus, Tokyo, Japan). MitoTracker Red CMXRos (MTR; Molecular Probes-Life Technologies, M-7512) staining (200 nM, 30 min at 37°C) was also performed to evaluate the integrity of the mitochondrial membrane potential.

SA-β-Gal Staining {#s0004-0007}
-----------------

Senescence-associated β-galactosidase (SA-β-Gal) staining was performed using HBEC grown on 24-well culture plates according to the manufacturer\'s instructions (BioVision, K802-250).

Measurement of ROS production {#s0004-0008}
-----------------------------

HBEC, at a density of 3 × 10^4^ per well, were seeded in a 96-well microplate (Thermo Fisher Scientific, 237105). DCFH-DA (Cell Biolabs, STA-342) was used to measure total cellular ROS according to the manufacturer\'s instructions. After incubation with DCFH-DA (10 μM) for 10 min at 37°C, fluorescence of DCF was measured at an excitation wavelength of 485 nm and an emission wavelength of 535 nm with a fluorescence microplate reader (Infinite F 200) (Tecan Japan, Kanagawa, Japan). Mitochondrial ROS production was analyzed by dihydrorhodamine 123 (DHR 123) and MitoSOX Red staining according to the manufacturer\'s instructions. The staining was evaluated with a fluorescence microscope (Olympus BX60, Tokyo, Japan).

Western blotting {#s0004-0009}
----------------

HBEC grown on 6-well culture plates were lysed in RIPA buffer (Thermo Fisher Scientific, 89900) with protease inhibitor cocktail (Roche Diagnostics, 11697498001) and 1 mM sodium orthovanadate. Western blotting was performed as previously described.[@cit0008] For each experiment, equal amounts of total protein were resolved by 10--15% SDS-PAGE. After SDS-PAGE, proteins were transferred to polyvinylidene difluoride membrane (Millipore, ISEQ00010), and incubation with specific primary antibody was performed for 1 h at room temperature. After washing several times with PBST (0.1% polyoxyethylene \[20\] sorbitan monolaurate \[Wako, 166-21213\] in PBS \[Wako, 041-20211\]), the membrane was incubated by anti-rabbit IgG, HRP-linked secondary antibody (Cell Signaling Technology, 7074) or anti-mouse IgG, HRP-linked secondary antibody (Cell Signaling Technology, 7076), followed by chemiluminescence detection (GE Healthcare, RPN2232) with LAS-4000 UVmini system (Fujifilm, Tokyo, Japan). To compare the PINK1 and PARK2 expression levels in lung homogenates between different experimental sets, one homogenate sample from a normal patient was selected as a loading control for all western blotting and used for further normalization of densitometric data analysis.

Statistics {#s0004-0010}
----------

Data are shown as the average (±SEM) taken from at least 3 independent experiments. The Student *t* test was used for comparison of 2 data sets and analysis of variance (one-way ANOVA with Bonferroni post hoc test) for multiple data sets. Linear regression analysis was used to compare PARK2 and PINK1 expression levels in lung homogenates to percentage of forced expiratory volume in 1 s/forced vital capacity (FEV~1~/FVC). Significance was defined as *P* \< 0.05. Statistical software used was Prism v.5 (GraphPad Software, Inc., San Diego, CA).
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[^1]: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; NA, not assessed; NS, not statistically significant; SI, Smoking index; Values are mean ± SD.

[^2]: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; %FEV1, percentage predicted forced expiratory volume in 1 second.
